Author

C. Burn Aschner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Organism:plant (other)· 1

Frequent Co-Authors

J.-P. Julien· 2 shared K. Prieto· 2 shared A. Jetha· 1 shared A. Obraztsova· 1 shared A. Sultana· 1 shared B. Mordmueller· 1 shared B. Poon· 1 shared B. Treanor· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J.-P. Julien

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular and functional properties of human Plasmodium falciparum CSP C-terminus antibodies

O. E. Oludada, G. Costa, C. Burn Aschner, A. Obraztsova, K. Prieto, C. Canetta, S. L. Hoffmann, P. Kremsner, B. Mordmueller, R. Murugan, J.-P. Julien, E. A. Levashina, H. Wardemann

This study characterizes human antibodies targeting the PfCSP C-terminal domain, finding limited protective activity and suggesting exclusion from malaria vaccine design.

bioRxiv · Jan 19, 2023 · PreprintImmunology

Antibody avidity and multi-specificity combined to confer protection against SARS-CoV-2 and resilience against viral escape

C. Burn Aschner, K. Muthuraman, I. Kucharska, H. Cui, K. Prieto, M. S. Nair, M. Wang, Y. Huang, N. Christie-Holmes, B. Poon, J. Lam, A. Sultana, R. Kozak, S. Mubareka, J. L. Rubinstein, , J.-P. Julien

This study develops a multimeric antibody platform (Multabody) that enhances neutralization potency and breadth against SARS-CoV-2 and its variants through avidity and multi-specificity.

bioRxiv · Oct 23, 2022 · PreprintImmunology